Clinical Trial Update: FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing FTC/RPV/TDF impact on T-cell activation, CD4+ T-cell counts, inflammatory biomarkers, and viral reservoir in HIV-1 infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• FTC/RPV/TDF

Snippet

Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Conditions: HIV-1 Infection | Phase 4 | Status: COMPLETED | Results posted: 2018-01-12